RGC-1502

RGC-1502 is an oncology program from Rgene Corporation/ABVC BioPharma being developed for pancreatic cancer as part of a clinical plan branded under BLEX 404, an oral liquid investigational drug evaluated in combination with gemcitabine. Public materials identify RGC-1502 as the pancreatic cancer program while referring to the study drug as BLEX 404; detailed mechanism of action for BLEX 404/RGC-1502 has not been disclosed in the cited sources. A Phase II trial is described to assess safety, dose, and response rate of BLEX 404 oral liquid plus gemcitabine in pancreatic cancer patients, sponsored by Rgene Corporation, with ABVC’s subsidiary BioKey contracted to guide the program through Phase II under FDA IND requirements.

Other names

BLEX 404BLEX404BLEX-404